Guardant Health director Azar Alex M II sold 826 shares at $175 per share, a transaction equal to about 50.0% of the director’s prior holding. The sale matters to investors because the reported transaction covered about half of that prior position, while the director’s remaining ownership was reported separately.
Key Highlights
- Azar Alex M II sold 826 Guardant Health shares at $175 per share.
- The sale took place on Sept. 16, 2026, under transaction code S.
- The Guardant Health share sale represented about 50.0% of Azar Alex M II’s prior holding.
Director Azar Alex M II sold 826 Guardant Health (NASDAQ: GH) shares at $175 per share. The transaction represented about 50.0% of the director’s prior holding.
826 Shares Sold at $175
The transaction took place on Sept. 16, 2026. Its reported price was $175 for each share, covering 826 shares in total. Azar Alex M II continued to own Guardant Health shares after the transaction.
Sale Covered About Half of Prior Holding
The reported 50.0% figure measures the sale against Azar Alex M II’s prior Guardant Health holding. Guardant Health remains the subject company associated with the reported director transaction.
FAQs
Q: How many Guardant Health shares did Azar Alex M II sell?
A: Azar Alex M II sold 826 Guardant Health shares at $175 per share. The transaction was recorded on Sept. 16, 2026.
Q: What percentage of Azar Alex M II’s prior holding did the sale represent?
A: The Guardant Health share sale represented about 50.0% of Azar Alex M II’s prior holding. The percentage applies to the reported transaction.
Q: Who sold Guardant Health shares?
A: Director Azar Alex M II sold 826 shares of Guardant Health. The company trades on the Nasdaq under the ticker GH.
Q: When did the transaction occur and at what price?
A: The transaction took place on Sept. 16, 2026. Each of the 826 shares was sold at a reported price of $175.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.